JBIO vs GPCR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
JBIO · Jade Biosciences$15.31 ▲ 1.66%
GPCR · Structure Therapeutics$16.13 ▼ 5.78%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- JBIO +26.0%
- GPCR -54.3%
Head to head
| Metric | JBIO | GPCR |
|---|---|---|
| Price | $15.31 | $16.13 |
| Change today | ▲ 1.66% | ▼ 5.78% |
| Market cap | $1.06B | $1.15B |
| Return, 3 months | -28.2% | -67.1% |
| Return, year to date | -0.8% | -76.8% |
| Return, 1 year | +27.6% | -53.0% |
| P/E (TTM) | – | – |
| P/B | 2.3 | 0.9 |
| P/E percentile vs own 5y | 11th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -39.2% | -120.3% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -51.4% | -29.5% |
| Analyst target vs. price | +244.0% | +542.7% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 51 | 22 |
| 30-day volatility | 53.3% | 61.9% |
| Max drawdown, 1 year | -50.1% | -82.8% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GPCR is the largest of the group by market value.
- JBIO has returned the most over the past year.
- JBIO has been the calmest stock over the last 30 days.